[go: up one dir, main page]

DK3229843T3 - Farmaceutisk sammensætning, præparat og anvendelser deraf - Google Patents

Farmaceutisk sammensætning, præparat og anvendelser deraf Download PDF

Info

Publication number
DK3229843T3
DK3229843T3 DK15801384.7T DK15801384T DK3229843T3 DK 3229843 T3 DK3229843 T3 DK 3229843T3 DK 15801384 T DK15801384 T DK 15801384T DK 3229843 T3 DK3229843 T3 DK 3229843T3
Authority
DK
Denmark
Prior art keywords
applications
preparation
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
DK15801384.7T
Other languages
English (en)
Inventor
Agnès Pottier
Marie-Edith Meyre
Matthieu Germain
Céline Berjaud
Audrey Darmon
Original Assignee
Curadigm Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curadigm Sas filed Critical Curadigm Sas
Application granted granted Critical
Publication of DK3229843T3 publication Critical patent/DK3229843T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK15801384.7T 2014-11-25 2015-11-24 Farmaceutisk sammensætning, præparat og anvendelser deraf DK3229843T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306871 2014-11-25
PCT/EP2015/077423 WO2016083331A1 (en) 2014-11-25 2015-11-24 Pharmaceutical composition, preparation and uses thereof

Publications (1)

Publication Number Publication Date
DK3229843T3 true DK3229843T3 (da) 2020-03-09

Family

ID=52013979

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15801384.7T DK3229843T3 (da) 2014-11-25 2015-11-24 Farmaceutisk sammensætning, præparat og anvendelser deraf

Country Status (11)

Country Link
US (2) US20170258937A1 (da)
EP (1) EP3229843B1 (da)
JP (1) JP6722688B2 (da)
AR (1) AR102778A1 (da)
DK (1) DK3229843T3 (da)
ES (1) ES2774365T3 (da)
LT (1) LT3229843T (da)
PL (1) PL3229843T3 (da)
PT (1) PT3229843T (da)
TW (1) TW201628644A (da)
WO (1) WO2016083331A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014273043B2 (en) 2013-05-30 2019-02-07 Nanobiotix Pharmaceutical composition, preparation and uses thereof
PL3223796T3 (pl) 2014-11-25 2021-12-20 Curadigm Sas Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt
UA124572C2 (uk) 2015-05-28 2021-10-13 Нанобіотікс Наночастинки для застосування як терапевтичної вакцини
CN117042807A (zh) * 2020-11-30 2023-11-10 安必圣有限责任公司 用抗体片段修饰且装载有细胞毒性药的多特异性人类白蛋白纳米颗粒

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT75469A (en) * 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
GB9509321D0 (en) 1995-05-09 1995-06-28 Zylepsis Ltd Methods of and substances for inhibiting oxidative enzymes
RU2006101216A (ru) * 2003-08-01 2007-07-20 Амген Инк. (US) Кристаллические полипептиды 2 фактора некроза опухолей
ES2531732T3 (es) 2003-12-22 2015-03-18 Bracco Suisse Sa Montaje de microvesícula rellena de gas para imagenología de contraste
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
AU2007247770B2 (en) 2006-05-04 2013-07-18 Reformpharm Pty Ltd Drug release from nanoparticle-coated capsules
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
WO2009105774A2 (en) 2008-02-21 2009-08-27 Sequoia Pharmaceuticals, Inc. Amino acid inhibitors of cytochrome p450
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US20130023714A1 (en) * 2008-10-26 2013-01-24 Board Of Regents, The University Of Texas Systems Medical and Imaging Nanoclusters
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
CN102781472B (zh) 2010-02-17 2014-07-02 国立大学法人神户大学 放射线治疗剂
KR101786142B1 (ko) * 2010-03-26 2017-10-17 아브락시스 바이오사이언스, 엘엘씨 간세포 암종의 치료 방법
US9782342B2 (en) * 2010-10-11 2017-10-10 Wichita State University Composite magnetic nanoparticle drug delivery system
WO2012104277A2 (en) 2011-01-31 2012-08-09 Nanobiotix Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles.
JP6158714B2 (ja) 2011-01-31 2017-07-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ ナノ粒子デリバリーシステム、その製造および使用
JP2015515462A (ja) * 2012-03-20 2015-05-28 イェシバ・ユニバーシティＹｅｓｈｉｖａ Ｕｎｉｖｅｒｓｉｔｙ 輸血の有効性を高める方法
ITRM20120480A1 (it) 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
US20140186447A1 (en) * 2012-12-28 2014-07-03 Abraxis Bioscience, Llc Nanoparticle compositions of albumin and paclitaxel
US20140213765A1 (en) 2013-01-25 2014-07-31 I-Liang Lee Albumin tissue scaffold
AU2014273043B2 (en) * 2013-05-30 2019-02-07 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
JP2018500298A (ja) 2014-11-25 2018-01-11 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医薬組成物、その調製及び使用
PL3223796T3 (pl) 2014-11-25 2021-12-20 Curadigm Sas Kompozycje farmaceutyczne, ich wytwarzanie i zastosowania
AU2015352685B2 (en) 2014-11-25 2020-09-17 Nanobiotix Pharmaceutical composition, preparation and uses thereof
FI3229776T3 (fi) 2014-11-25 2023-08-15 Curadigm Sas Farmaseuttinen koostumus, joka yhdistää ainakin kaksi erillistä nanopartikkelia ja farmaseuttisen yhdisteen, sen valmistus ja käytöt

Also Published As

Publication number Publication date
AR102778A1 (es) 2017-03-22
US20170258937A1 (en) 2017-09-14
WO2016083331A1 (en) 2016-06-02
JP6722688B2 (ja) 2020-07-15
LT3229843T (lt) 2020-05-25
TW201628644A (zh) 2016-08-16
US20180339062A1 (en) 2018-11-29
US11191846B2 (en) 2021-12-07
EP3229843A1 (en) 2017-10-18
JP2017538782A (ja) 2017-12-28
EP3229843B1 (en) 2020-01-01
ES2774365T3 (es) 2020-07-20
PL3229843T3 (pl) 2020-06-29
PT3229843T (pt) 2020-03-06

Similar Documents

Publication Publication Date Title
IL276695B (en) Antibodies, pharmaceutical preparations and their uses
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
BR112016023628A2 (pt) composições farmacêuticas.
DK3018183T3 (da) Halogenolefinbaseret sammensætning og anvendelse deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf
DK3209773T3 (da) Prolintolerante tripeptidylpeptidaser og anvendelser deraf
IL290114A (en) Pharmaceutical preparations, their preparation and uses
DK3199161T3 (da) Farmaceutisk præparat
DK3223796T3 (da) Farmaceutiske sammensætninger, fremstilling og anvendelser deraf
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf
HUE056408T2 (hu) Kombinációk és alkalmazásaik
IL252397A0 (en) Pharmaceutical preparations, their preparation and uses
DK3110837T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formule-ringer og anvendelse deraf
HUE048503T2 (hu) Dihidropirimidin-2-on vegyületek és gyógyszerészeti alkalmazásai
DK3365321T3 (da) Solabegron-zwitterion og anvendelser deraf
DK3229843T3 (da) Farmaceutisk sammensætning, præparat og anvendelser deraf
DK3383397T3 (da) Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin
DK3302483T3 (da) Farmaceutiske sammensætninger og anvendelse deraf
DK3288933T3 (da) Oxindolforbindelser og farmaceutiske sammensætninger deraf
IL262929A (en) Preparations for treatment, methods for their preparation and their uses
DK3166960T3 (da) Lav-substituerede polymyxiner og sammensætninger deraf
DK3089740T3 (da) Farmaceutisk sammensætning
DK3215130T3 (da) Farmaceutisk sammensætning omfattende bisoprolol og perindoril
TH1501007100A (th) องค์ประกอบทางเภสัชกรรม, การเตรียม และการใช้ของมัน
TH1501004545A (th) องค์ประกอบทางเภสัชกรรมที่มีเด็กซ์คีโตโพรเฟนและทรามาดอล